Emmaus Life Sciences Inc 's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Emmaus Life Sciences Inc 's ROA in the fourth quarter of 2025?
Emmaus Life Sciences Inc recorded a cumulative net loss of $-7 million during 12 months ending in the fourth quarter of 2025, resulting in a negative return on assets (ROA) of -31.81%.

However, within the Healthcare sector 510 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the second quarter of 2025 from to 4298.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Dec 31 2025) IV. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter
Y / Y Total Assets Change	-18.35 %	-3 %	-19.44 %	-32.04 %	-43 %
Y / Y Net Income Change	-	-	-	-	2626.87 %
Net Income (TTM) in million	-7	-3	-4	-6	-3
Return On Assets (TTM)	-31.81 %	-14.27 %	-18.55 %	-25.55 %	-12.51 %
EMMAW's Total Ranking	# 4298	#	# 3422	# 3573	# 4319
Total Assets (TTM) in million	21	23	22	23	26
Seq. Total Assets Change	-8.17 %	3.85 %	-1.47 %	-13.1 %	9.09 %
Seq. Net Income Change	-	-	-	-	-

EMMAW's 5 Years Annual ROA >> Back to EMMAW Management Effectiveness >> Compare EMMAW ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 208
Sector	# 511
Overall	# 4260

Return On Assets Statistics
High	Average	Low
2.24 %	-113.68 %	-1096.34 %
(Dec 31 2020)		(Jun 30 2018)

Financial Statements
Emmaus Life Sciences Inc 's Assets	$ 21 million	EMMAW's Balance sheet
Emmaus Life Sciences Inc 's Income	$ -2 million	Quarterly EMMAW's Income Statement
EMMAW's Income by Division		See EMMAW's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-6.04 %	-32.04 %	-28.87 %	-12.37 %	-2.75 %
Total Assets in million	21	23	34	47	54
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-7	-6	-4	-11	-16
Annual Return On Assets	-34.95 %	-28.29 %	-11.12 %	-22.51 %	-29.61 %

EMMAW's 5 Years Annual ROA >> Back to EMMAW Management Effectiveness >> Compare EMMAW ROA to its Competitors

More Return On Assets Ratios
EMMAW's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
EMMAW's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for EMMAW's Competitors
Subscribers only: Roa for Emmaus Life Sciences Inc 's Suppliers
Subscribers only: Return On Assets for EMMAW's Customers

You may also want to know
EMMAW's Roi	EMMAW's Inventory Turnover Ratio	EMMAW's Growth Rates	EMMAW's Dividend Comparisons
	EMMAW's Profitability Ratios	EMMAW's Asset Turnover Ratio	EMMAW's Dividend Growth
EMMAW's Roe	EMMAW's Valuation Ratios	EMMAW's Financial Strength Ratios	EMMAW's Dividend Payout Ratio

Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector

ROA

Date modified: 2026-09-08T15:11:39+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.